Saturday 17 October 2026 Export AMLX’s income statement to Excel — free account

Amylyx Pharmaceuticals, Inc.

AMLX Healthcare Drug Manufacturers Specialty & Generic

Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023. In the quarter to June 2026, revenue fell 100.6%, EPS grew 15.2% and free cash flow fell 24.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

26.34 1.31 −4.74%

Follow AMLX

Alert me

Market cap: $3.5B
P/E: 0.0×
Fwd P/E: −9.2×
Dividend yield: —
F-score: 3/9
Altman Z: −2.95
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.15

Total sells 10.14

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	1	—	—	—	—	1	—	—	—	—	—
Sell	—	1	5	5	5	—	—	—	1	—	5	1

Insider Ownership 4.40%

Capital & Financial Ratios $m

Market Cap 3,470.00

Revenue 87.37

Net Income (152.09)

Free Cash Flow (130.72)

Net Debt (250.76)

Current Ratio 12.12

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (9.21)

P/S ratio 33.52

P/B ratio 12.25

Past 5Y EPS Growth —

This Y EPS Growth 2.20%

Next Y EPS Growth 24.34%

Next Y revenue growth (61.29%)

Next 5Y EPS Growth 49.92%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 95.28%

10-year low 10-year high

P/B against its own 10 years 90.97%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2018	0.42	0.42
2017	0.60	0.24 0.36

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	371	177	317	251
Receivables	40	0	0	—
Inventory	38	—	—	—
Other	—	—	—	—
	465	189	324	256

	2023	2024	2025	Q'26
Payables	22	3	4	6
ST’ Debt	—	—	—	—
Other	—	—	—	—
	82	28	23	21

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	574.28%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	124.63%	(3.59%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	89	(1)	0	(1)	87
’23	71	98	103	108	381
’22	—	—	0	22	22
’21	—	—	0	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(37)	(31)	—	—	—
’25	(40)	(25)	(30)	(28)	(123)
’24	0	(67)	(42)	(59)	(168)
’23	(5)	9	(5)	14	12
’22	(41)	(46)	(43)	(50)	(180)
’21	(13)	(13)	(21)	(28)	(75)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(41)	(31)	—	—	—
’25	(40)	(25)	(30)	(28)	(123)
’24	(1)	(67)	(78)	(59)	(204)
’23	(5)	8	(6)	13	11
’22	(41)	(48)	(44)	(50)	(182)
’21	(13)	(13)	(21)	(28)	(75)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.37)	(0.39)	—	—	—
’25	(0.42)	(0.46)	(0.37)	(0.30)	(1.53)
’24	(1.75)	(1.07)	(1.07)	(0.55)	(4.43)
’23	0.02	0.31	0.30	0.07	0.70
’22	(0.93)	(0.93)	(0.92)	(0.65)	(3.39)
’21	(2.33)	(3.41)	(3.42)	(4.19)	(13.35)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	6.51	11.82	1.58	2.60	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	39.78	41.93	19.95	16.96
People
People	Employees	—	—	—	—	110	205	262	384	123	136
	Revenue/emp, $m	—	—	—	—	0.01	0.00	0.08	0.99	0.71	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	1	0	22	381	87	—
	Gross margin, %	—	—	—	—	100.00	100.00	86.54	93.32	(42.65)	—
	EBT	—	—	—	—	(42)	(88)	(198)	54	(302)	(145)
	EBT margin, %	—	—	—	—	(6,504.62)	(30,852.98)	(888.89)	14.26	(345.81)	0.00
	Net income	—	0	—	—	(42)	(88)	(198)	49	(302)	(145)
	Depreciation	—	—	—	—	0	0	(2)	(9)	(9)	(5)
Per share, $
Per share, $	Revenue	—	—	—	—	0.11	0.04	0.38	5.66	1.28	0.00
	Earnings	—	—	—	—	(6.96)	(13.35)	(3.39)	0.73	(4.43)	(1.53)
	Cash flow	—	—	—	—	(6.04)	(11.36)	(3.07)	0.18	(2.46)	(1.30)
	Capex	—	—	—	—	(0.02)	(0.05)	(0.04)	(0.02)	(0.53)	0.00
	Free cash flow	—	—	—	—	(6.06)	(11.41)	(3.12)	0.16	(2.99)	(1.31)
	Book value	—	—	—	—	0.88	13.39	5.82	6.45	2.42	3.23
	Shares, m	—	—	—	—	6	7	58	67	68	95
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	20.51	0.00	—
	P/S	—	—	—	—	0.00	0.00	0.00	2.64	2.95	—
	P/B	—	—	—	—	0.00	0.00	6.18	2.32	1.56	—
	EV/Sales	—	—	—	—	0.00	0.00	0.00	1.67	0.94	—
	EV/FCF	—	—	—	—	(0.32)	(0.32)	(9.64)	59.61	(0.40)	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	(37)	(75)	(180)	12	(168)	(123)
	Capex	—	—	—	—	0	0	(3)	(1)	(36)	0
	Free cash flow	—	—	—	—	(37)	(75)	(182)	11	(204)	(123)
Balance, $m
Balance, $m	Working capital	—	—	—	—	6	88	336	383	161	301
	Total debt	—	—	—	—	1	—	—	—	—	—
	Net debt	—	—	—	—	(11)	(96)	(347)	(371)	(177)	(317)
	Shareholders’ equity	—	—	—	—	5	88	341	433	165	305
Returns, %
Returns, %	ROA	—	—	—	—	(599.55)	(146.90)	(79.82)	10.84	(84.87)	(55.00)
	ROIC	—	—	—	—	0.00	0.00	0.00	39.07	0.00	0.00
	ROE	—	—	—	—	0.00	80.71	(209.43)	12.73	(100.88)	(61.59)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Dec 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RGC Regencell Bioscience Holdings Limited	$4.7B	— (loss-making)	—	—	—	+57.15% (above 0%: growing)	0.00%	—	Compare
INDV Indivior Pharmaceuticals Inc.	$4.0B	11.2×	11.8×	+13.58% (above 0%: growing)	+580.00% (above 0%: growing)	+58.57% (above 0%: growing)	85.42%	46.36%	Compare
AMLX Amylyx Pharmaceuticals, Inc.	$3.5B	— (loss-making)	— (loss-making)	−100.61% (below 0%: shrinking)	n/m	−24.50% (below 0%: shrinking)	100.00%	0.00%
LQDA Liquidia Corporation	$3.1B	21.9×	18.5×	+1,842.73% (above 0%: growing)	n/m	+270.23% (above 0%: growing)	93.27%	49.81%	Compare
HCM HUTCHMED (China) Limited Sponsored ADR	$2.4B	— (loss-making)	—	+510.07% (above 0%: growing)	+419.25% (above 0%: growing)	+113.21% (above 0%: growing)	60.90%	0.00%	Compare
PBH Prestige Consumer Healthcare Inc.	$2.3B	13.9×	10.3×	+6.48% (above 0%: growing)	−36.46% (below 0%: shrinking)	−14.19% (below 0%: shrinking)	51.25%	19.77%	Compare
SUPN Supernus Pharmaceuticals, Inc.	$2.3B	— (loss-making)	103×	+32.40% (above 0%: growing)	n/m	−109.26% (below 0%: shrinking)	84.63%	(26.46%)	Compare
PRGO Perrigo Company plc	$2.3B	— (loss-making)	— (loss-making)	−3.17% (below 0%: shrinking)	n/m	+18.37% (above 0%: growing)	30.69%	2.31%	Compare
ALVO Alvotech	$2.1B	— (loss-making)	8.9×	+2,310.95% (above 0%: growing)	−99.51% (below 0%: shrinking)	−496.58% (below 0%: shrinking)	56.47%	9.14%	Compare
Median of peers	$2.4B	13.9×	11.8×	+32.40%	+191.40%	+37.76%	58.69%	9.14%

All 86 Drug Manufacturers Specialty & Generic stocks →

Amylyx Pharmaceuticals, Inc. (AMLX) key facts

Concern: Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
Concern: Amylyx Pharmaceuticals, Inc. reported a net loss of $144.7 million, or a loss of $1.53 per share, for fiscal 2025.
Amylyx Pharmaceuticals, Inc. (AMLX) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, AMLX traded at $26.34, a market capitalization of $3.5 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 33.5× sales.
Return on equity was −61.6% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −2.95 (distress zone) for fiscal 2024.